312 related articles for article (PubMed ID: 12414349)
41. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
42. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
[TBL] [Abstract][Full Text] [Related]
43. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
[TBL] [Abstract][Full Text] [Related]
44. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
[TBL] [Abstract][Full Text] [Related]
45. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.
Buzoianu AD; Militaru FC; Vesa SC; Trifa AP; Crişan S
Blood Cells Mol Dis; 2013 Mar; 50(3):166-70. PubMed ID: 23159639
[TBL] [Abstract][Full Text] [Related]
46. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.
van Schie RM; Wessels JA; Verhoef TI; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; Visser LE; Teichert M; Hofman A; Buhre PN; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2012 Dec; 13(16):1917-23. PubMed ID: 23215884
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
[TBL] [Abstract][Full Text] [Related]
49. Genetic and environmental risk factors for oral anticoagulant overdose.
Verstuyft C; Robert A; Morin S; Loriot MA; Flahault A; Beaune P; Funck-Brentano C; Jaillon P; Becquemont L
Eur J Clin Pharmacol; 2003 Mar; 58(11):739-45. PubMed ID: 12634980
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
[No Abstract] [Full Text] [Related]
51. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
Verde Z; Ruiz JR; Santiago C; Valle B; Bandrés F; Calvo E; Lucía A; Gómez Gallego F
PLoS One; 2010 Jun; 5(6):e11210. PubMed ID: 20585445
[TBL] [Abstract][Full Text] [Related]
52. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
53. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
54. Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
André-Kerneïs E; Leroy-Matheron C; Gouault-Heilmann M
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):761-4. PubMed ID: 14614357
[TBL] [Abstract][Full Text] [Related]
55. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
56. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
[TBL] [Abstract][Full Text] [Related]
57. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients.
Montes R; Nantes O; Alonso A; Zozaya JM; Hermida J
Br J Haematol; 2008 Dec; 143(5):727-33. PubMed ID: 18950464
[TBL] [Abstract][Full Text] [Related]
58. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
[TBL] [Abstract][Full Text] [Related]
59. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes.
Kovac MK; Rakicevic LB; Radojkovic DP
J Thromb Thrombolysis; 2011 Oct; 32(3):368-71. PubMed ID: 21638223
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
